Effect of platelet activating factor on embryonic development and implantation in the mouse.
Platelet activating factor (PAF) was administered to female mice in order to investigate its effect on ovulation rate and on oocyte quality including their in-vitro embryonic development, implantation and uterine receptivity. In experiment 1, 4-week-old female mice were assigned to receive PAF or phosphate buffered saline for 4 consecutive days. On the second day of this treatment, pregnant mares' serum gonadotrophin was administered and human chorionic gonadotrophin (HCG) 48 h later, after which copulation occurred. Oocytes were collected on the following day and evaluated. The mean number of oocytes and zygotes (two pronuclear stage embryos) recovered from the PAF-treated group was not different from the control group (31 versus 27), but the proportion of zygotes was higher in PAF-treated group than in controls (83 versus 68%, P < 0.05, PAF versus controls). Although the rate of in-vitro first cleavage was not different in the two groups (82 versus 69% respectively), hatching was higher in the PAF-treated group than control mice (99 versus 83%, P < 0.01). In experiment 2, the in-vitro developed blastocysts from experiment 1 were transferred into the uterus of day 3 pseudopregnant PAF-treated or control recipients. Three different combinations of intrauterine transfer were performed; PAF embryo to control recipient (PAF-->C: n = 19), control embryo to PAF recipient (C-->PAF: n = 19), and control embryo to control recipient (C-->C: n = 22). Implantation and abortion were assessed on day 19 posttransfer. The implantation rate of C-->PAF (23.7%) was lower than C-->C (31.1%, P < 0.05), but was not different from PAF-->C (31.2%). Further, C-->PAF showed a higher abortion rate per embryo (29.6%) than PAF-->C (12.7%, P < 0.05), but was not different from C-->C (24.4%). In the present study, PAF administration enables females to produce oocytes with a higher potential for fertilization, in-vitro development and implantation, but has a detrimental effect on uterine receptivity to embryos.
Fukuda
A I
AI
Department of Obstetrics and Gynecology, James H. Quillen College of Medicine, College of Medicine, East Tennessee State, Johnson City 37614-0569, USA.
Breuel
K F
KF
D000818:Animals; D001755:Blastocyst / Q000502:physiology; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D010064:Embryo Implantation / Q000187:drug effects*; D004624:Embryo Transfer; D004622:Embryo, Mammalian / Q000187:drug effects*; D005314:Embryonic and Fetal Development; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D051379:Mice; D009865:Oocytes / Q000166:cytology; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011247:Pregnancy; D011555:Pseudopregnancy; D015053:Zygote / Q000254:growth & development
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D010972:Platelet Activating Factor